



QNZ (EVP4593)

Cat. No.:	OB0225WX-2612
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	5 mg; 25 mg; 1 g; 2 g

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	QNZ (EVP4593) is a potent chemical inhibitor that suppresses both TNF-alpha production and NF-kappaB activation, with IC50 values of 7 nM and 11 nM, respectively.
Synonym	545380-34-5; 6-Amino-4-(4-phenoxyphenylethylamino)quinazoline; N4-(4-phenoxyphenylethyl)quinazoline-4,6-diamine; 4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine; NF-kB activation inhibitor; EVP-4593; N4-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine; EVP 4593; MFCD06411436; AG-F-89549; Curator_000005; 6-amino-4-(4-phenoxyphenylethylamino)quinazoline; 4,6-Quinazolinediamine, N4-[2-(4-phenoxyphenyl)ethyl]-; N~4~-2-(4-Phenoxyphenyl)ethyl]quinazoline-4,6-diamine
CAS No.	545380-34-5
Compound CID	509554
Formula	C ₂₂ H ₂₀ N ₄
Formula Weight	356.42

Specification

IUPAC Name	4-N-[2-(4-Phenoxyphenyl)ethyl]quinazoline-4,6-diamine
InChI	InChI=1S/C22H20N4O/c23-17-8-11-21-20(14-17)22(26-15-25-21)24-13-12-16-6-9-19(10-7-16)27-18-4-2-1-3-5-18/h1-11,14-15H,12-13,23H2,(H,24,25,26)
InChI Key	IBAKVEUZKHOWNG-UHFFFAOYSA-N
SMILES string	C1=CC=C(C=C1)OC2=CC=C(C=C2)CCNC3=NC=NC4=C3C=C(C=C4)N



Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	QNZ (EVP4593) is applied in signal transduction research as a potent NF-kappaB inhibitor to investigate the disruption of pro-inflammatory gene expression and its protective effects in models of neurodegeneration.

Library Information

Target	NF-κB; TNF-alpha
Receptor	NF-κB; TNF-alpha
Pathways	NF-κB
Plate Number	L6700-06
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	5 mg/mL; 14.03 mM
ALogP	4.454
HBA_Count	3
HBD_Count	2
Rotatable Bond	6